Patient Diagnosis_______________________________________________Allergies_____________________________________ Medication/ Dose /Route Humlin R; novoLIN (insulin regular) Times Classification /Action Pancreatic hormone (replacement

of endogenous insulin) Q6hr pregnancy risk B Action-promotes storage of bodys fuels, facilitates the transport of various metabolites and ions across cell membrane and stimulates the synthesis of glycogen from glucose of fats from lipids and of proteins from amino acids. Reacts with specific receptor sites on the cell. Signs of OD: hypoglycemia Adverse reactions: hypoglycemia, ketoacidosis that can be controlled by dose adjustments and reactions at injection sites including lipidystrophy Reason for this patient Treatment of DM II that cannot be controlled by diet, exercise or other agents Nursing Implications *Contraindicated in pts with known allergy to drug and during episodes of hypoglycemia *review extensive list of interactions *rotate vial, do not shake to create bubbles *select site free of bruising and scarring to ensure good absorption *Give med subQ route only and rotate injection sites to avoid tissue damage *Monitor response carefully for adverse effects; S&S of hypoglycemia during peak time *Verify name of insulin given and caution when mixing insulin *Can be given IV *Cannot mix with glargine*routine mixed with NPH *The higher the dose the higher the effect

2-15 units SubQ Short-acting Onset 30-60 min Peak 2-3 hours Duration 4-6 hours Sliding Scale

T1/2 = about 9 min Metabolism varies with prep.; metabolized at cellular level Antagonist agent:

Nursing2011 Drug Handbook with Web Toolkit (Nursing Drug Handbook (LWW)) (Thirty-first Edition ed., pp. 1073-1076). (2010). Parenteral Antidiabetics and glucagon: Insulin regular. Philadelphia: Lippincott Williams & Wilkins.